Form 4: AbbVie Director Susan Quaggin Acquires Stock Equivalent Units

AbbVie Inc. Director Susan E. Quaggin acquired 81 stock equivalent units on June 30, 2025, valued at $185.62 per unit, as part of director fees credited to a grantor trust.

Summary

• Susan E. Quaggin, a Director of AbbVie Inc. (ABBV), acquired 81 stock equivalent units on June 30, 2025.
• These units were acquired at a price of $185.62 per unit.
• The acquisition represents director fees credited to a stock equivalent unit account under a grantor trust established by the director.
• The stock equivalent units are designed to earn the same return as if the fees were invested in AbbVie common stock.
• Payment for these units is generally made in cash at age 65 or upon retirement from the board.
• Following this transaction, Susan E. Quaggin beneficially owns a total of 562 stock equivalent units, which includes units previously acquired through a dividend reinvestment feature.

Sentiment

Score: 7

Explanation: The acquisition of stock equivalent units by a director is generally a positive signal, indicating alignment of interests and confidence in the company's long-term performance. As a routine compensation event, it contributes moderately positively to overall sentiment.

Positives

• Director Susan E. Quaggin increased her beneficial ownership in AbbVie through the acquisition of 81 stock equivalent units, aligning her financial interests with those of shareholders.
• The crediting of director fees to stock equivalent units under a grantor trust demonstrates a structured and long-term approach to director compensation, promoting commitment to the company's performance.

Future Outlook

The filing details a director compensation structure where stock equivalent units are paid in cash generally at age 65 or upon retirement from the board, indicating a long-term alignment of director interests with the company's future performance.

Management Comments

• Director fees are credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board.
• The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.
• The reported balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Industry Context

This transaction is a routine insider filing (Form 4) common across publicly traded companies, reflecting director compensation practices that often include equity-linked instruments to align director interests with shareholder value. Such compensation structures are standard in the pharmaceutical and biotechnology industry, where long-term strategic vision is crucial.

Comparison to Industry Standards

• The use of stock equivalent units as part of director compensation is a common practice among large-cap pharmaceutical companies like AbbVie, similar to compensation structures seen at peers such as Pfizer (PFE), Johnson & Johnson (JNJ), and Merck (MRK).
• Crediting director fees to equity-linked accounts, which vest or are paid out upon retirement or a certain age, aligns with best practices in corporate governance, promoting long-term commitment and performance.

Corporate Governance

Stakeholder Impact

• Shareholders: The acquisition of stock equivalent units by a director aligns their interests with shareholders, potentially fostering long-term value creation.

Next Steps

• Continued crediting of director fees to stock equivalent unit accounts as per the established compensation plan.
• Future payment of stock equivalent units in cash, generally at age 65 or upon retirement from the board, as per the grantor trust terms.

Key Dates

Recommendation

Keywords

AbbVie, ABBV, Form 4, SEC filing, insider transaction, director compensation, stock equivalent units, corporate governance, beneficial ownership